Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05226598 for Metastatic Non-Small Cell Lung Cancer is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One trial matched filter criteria
Card View
Back to Search
Merck Sharp & Dohme LLCStudy of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Clinical Trial NCT05226598 is designed to study Treatment for Metastatic Non-Small Cell Lung Cancer. It is a Phase 3 interventional trial that is active, not recruiting, having started on 24 March 2022, with plans to enroll 739 participants. Led by Merck Sharp & Dohme LLC, it is expected to complete by 9 January 2026. The latest data from ClinicalTrials.gov was last updated on 13 November 2025.
Brief Summary
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.
Detailed Description
Effective as of Amendment 5, Participants receiving coformulation of pembrolizumab/vibostolimab plus chemotherapy will be transitioned to standard of care (SOC, pembrolizumab plus chemotherapy). Participants with access to approved standard of care (SOC) should be considered for discontinuation from the study. Those benefiting from pembrolizumab plus chemotherapy, but unable to access it as SOC outside the study, may continue on study and receive treatment with pembrolizumab plus chemotherapy until discontinuation criteria are met.
Official Title
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Conditions
Metastatic Non-small Cell Lung CancerPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- 7684A-007
- MK-7684A-007 (Other Identifier) (MSD)
- KEYVIBE-007 (Other Identifier) (MSD)
- jRCT2031220098 (Registry Identifier) (jRCT)
- 2023-506074-12-00 (Registry Identifier) (EU CT)
- U1111-1293-2114 (Registry Identifier) (UTN)
NCT ID Number
Start Date (Actual)
2022-03-24
Last Update Posted
2025-11-13
Completion Date (Estimated)
2026-01-09
Enrollment (Estimated)
739
Study Type
Interventional
PHASE
Phase 3
Status
Active, not recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Triple
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalMK-7684A + Chemotherapy Participants receive pembrolizumab/vibostolimab (co-formulation of 200mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous. | Pembrolizumab/vibostolimab Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations Carboplatin Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations Cisplatin Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations Paclitaxel Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations Nab-paclitaxel Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations Pemetrexed Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision |
Active ComparatorPembrolizumab + Chemotherapy Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous. | Carboplatin Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations Cisplatin Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations Paclitaxel Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations Nab-paclitaxel Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations Pemetrexed Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision Pembrolizumab Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1% | OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all participants with PD-L1 positive tumors (PD-L1 TPS≥1%). The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. | Up to approximately 29 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Overall Survival (OS) in All Participants | OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all randomized participants. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. | Up to approximately 29 months |
Progression-Free Survival (PFS) | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) was planned to be presented. | Up to approximately 29 months |
Objective Response Rate (ORR) | ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by blinded independent central review (BICR) was planned to be presented. | Up to approximately 29 months |
Duration of Response (DOR) | For participants who demonstrate a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was planned to be presented. | Up to approximately 29 months |
Change From Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 was planned to be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. | Baseline and Up to approximately 29 months |
Change From Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 | Change from baseline in the score of EORTC QLQ-C30 Items 1-5 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. | Baseline and Up to approximately 29 months |
Change From Baseline for Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 | Change from baseline in the score of EORTC QLQ-C30 Items 6-7 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. | Baseline and up to approximately 29 months |
Change From Baseline in Dyspnea Score (Item 8) on the EORTC QLQ-C30 | Change from baseline in the score of EORTC QLQ-C30 Item 8 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. | Baseline and Up to approximately 29 months |
Change From Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) | Change from baseline in the score of EORTC QLQ-LC13 Item 31 was planned to be presented. The EORTC QLQ-LC13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. | Baseline and Up to approximately 29 months |
Change From Baseline in Chest Pain Score (Item 40) on the EORTC QLQ- LC13 | Change from baseline in the score of EORTC QLQ-LC13 Item 40 was planned to be presented. The EORTC QLQ-LC13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. | Baseline and Up to approximately 29 months |
Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30 | TTD in the score of EORTC QLQ-C30 Items 29 and 30 was planned to be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ- C30 | TTD in the score of EORTC QLQ-C30 Items 1-5 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
TTD in Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 | TTD in the score of EORTC QLQ-C30 Items 6-7 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
TTD in Dyspnea Score (Item 8) on the EORTC QLQ-C30 | TTD in the score of EORTC QLQ-C30 Item 8 was planned to be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
TTD in Cough Score (Item 31) on the EORTC QLQ-LC13 | TTD in the score of EORTC QLQ-LC13 Item 31 was planned to be presented. The EORTC QLQ-LC13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
TTD in Chest Pain Score (Item 40) on the EORTC QLQ-LC13 | TTD in the score of EORTC QLQ-LC13 Item 40 was planned to be presented. The EORTC QLQ-LC13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 29 months |
Number of Participants Who Experienced One or More Adverse Events (AEs) | The number of participants who experienced an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. | Up to approximately 46 months |
Number of Participants Who Discontinued Study Intervention Due to an AE | The number of participants who discontinue study intervention due to an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. | Up to approximately 46 months |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
INCLUSION CRITERIA:
- A histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous NSCLC
- Has not received prior systemic treatment for metastatic NSCLC
- Has measurable disease based on RECIST 1.1, as determined by the local site assessment
- Has a life expectancy of at least 3 months
- Males: Use contraception unless confirmed to be azoospermic; Females: Women of childbearing potential use highly effective contraceptive method
Exclusion Criteria:
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Severe hypersensitivity to MK-7684, MK-7684A, pembrolizumab, chemotherapy components, and/or any of its excipients
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication
- Active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV), Hepatitis B or/and Hepatitis C virus
- Received prior systemic anticancer therapy for metastatic disease
- Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed
- History of allogeneic tissue/solid organ transplant
- Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
- Is unable or unwilling to take folic acid or vitamin B12 supplementation
- Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
Merck Sharp & Dohme LLC722 active trials to exploreNo contact data.
149 Study Locations in 19 Countries
Colorado
UCHealth Memorial Hospital-Heme Onc ( Site 0003), Colorado Springs, Colorado, 80909, United States
University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031), Fort Collins, Colorado, 80528, United States
Florida
Mayo Clinic in Florida ( Site 0022), Jacksonville, Florida, 32224, United States
Illinois
Mount Sinai Hospital ( Site 0011), Chicago, Illinois, 60608, United States
University of Chicago Medical Center ( Site 0015), Chicago, Illinois, 60637, United States
Maine
New England Cancer Specialists ( Site 0008), Scarborough, Maine, 04074, United States
Michigan
Cancer and Hematology Centers of Western Michigan ( Site 0002), Grand Rapids, Michigan, 49503, United States
Minnesota
Mayo Clinic in Rochester, Minnesota ( Site 0030), Rochester, Minnesota, 55905, United States
New York
Stony Brook University-Cancer Center ( Site 0013), Stony Brook, New York, 11794, United States
Pennsylvania
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012), Lancaster, Pennsylvania, 17604, United States
South Carolina
Charleston Oncology ( Site 0019), Charleston, South Carolina, 29414, United States
Virginia
University of Virginia Cancer Center ( Site 0018), Charlottesville, Virginia, 22903, United States
Buenos Aires
Centro de Oncología e Investigación de Buenos Aires ( Site 0203), Berazategui, Buenos Aires, B1884BBF, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0204), Mar del Plata, Buenos Aires, B7600FZO, Argentina
Buenos Aires F.D.
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0209), ABB, Buenos Aires F.D., C1199ABB, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0202), Buenos Aires, Buenos Aires F.D., C1431FWO, Argentina
Santa Fe Province
Sanatorio Parque ( Site 0205), Rosario, Santa Fe Province, 2000, Argentina
Hospital Provincial del Centenario ( Site 0212), Rosario, Santa Fe Province, 2002, Argentina
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0206), La Rioja, F5300COE, Argentina
Styria
Medizinische Universität Graz ( Site 0704), Graz, Styria, 8036, Austria
Tyrol
Medizinische Universitaet Innsbruck ( Site 0703), Innsbruck, Tyrol, 6020, Austria
Upper Austria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0705), Linz, Upper Austria, 4020, Austria
Kepler Universitätsklinikum ( Site 0707), Linz, Upper Austria, 4021, Austria
Vienna
Klinik Penzing-2. Lungenabteilung ( Site 0702), Vienna, Vienna, 1140, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0701), Vienna, 1210, Austria
Rio Grande do Norte
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0403), Natal, Rio Grande do Norte, 59075-740, Brazil
Rio Grande do Sul
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0405), Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
Santa Catarina
Clínica de Oncologia Reichow ( Site 0407), Blumenau, Santa Catarina, 89010-340, Brazil
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0406), Rio de Janeiro, 20230-130, Brazil
Hospital Paulistano ( Site 0401), São Paulo, 01321-001, Brazil
Region M. de Santiago
FALP-UIDO ( Site 0505), Santiago, Region M. de Santiago, 6900941, Chile
Centro de Oncología de Precisión ( Site 0515), Santiago, Region M. de Santiago, 7560908, Chile
Bradfordhill ( Site 0510), Santiago, Region M. de Santiago, 8420383, Chile
Región de la Araucanía
James Lind Centro de Investigación del Cáncer ( Site 0502), Temuco, Región de la Araucanía, 4800827, Chile
CIDO SpA-Oncology ( Site 0508), Temuco, Región de la Araucanía, 4810148, Chile
Región de Valparaíso
ONCOCENTRO APYS-ACEREY ( Site 0503), Viña del Mar, Región de Valparaíso, 2520598, Chile
Región del Biobío
Biocenter ( Site 0514), Concepción, Región del Biobío, 4070196, Chile
Centro de Investigación Oncológica del Norte ( Site 0504), Antofagasta, 1240000, Chile
Anhui
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2619), Hefei, Anhui, 230036, China
Beijing Municipality
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2602), Beijing, Beijing Municipality, 100142, China
Fujian
Fujian Provincial Cancer Hospital-oncology department ( Site 2621), Fuzhou, Fujian, 350014, China
The First Affiliated hospital of Xiamen University ( Site 2626), Xiamen, Fujian, 361003, China
Guangdong
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine (, Guangzhou, Guangdong, 510515, China
Heilongjiang
Harbin Medical University Cancer Hospital-oncology of department ( Site 2604), Harbin, Heilongjiang, 150000, China
Henan
Henan Cancer Hospital ( Site 2608), Zhengzhou, Henan, 450000, China
Hubei
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2618), Wuhan, Hubei, 430022, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 2617), Wuhan, Hubei, 430030, China
Hunan
Xiangya Hospital Central South University-Oncology department ( Site 2627), Changsha, Hunan, 410008, China
The Second Xiangya Hospital of Central South University ( Site 2623), Changsha, Hunan, 410011, China
Hunan Cancer Hospital ( Site 2622), Changsha, Hunan, 410013, China
Jiangsu
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (, Nanjing, Jiangsu, 210000, China
Jiangxi
The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 2625), Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2624), Nanchang, Jiangxi, 330006, China
Jilin
Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, 132000, China
Shaanxi
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2607), Xi'an, Shaanxi, 710061, China
Shandong
Shandong Cancer Hospital-Oncology Department ( Site 2630), Jinan, Shandong, 250117, China
Shanghai Municipality
Fudan University Shanghai Cancer Center ( Site 2616), Shanghai, Shanghai Municipality, 200032, China
Shanghai Pulmonary Hospital-Oncology Department ( Site 2601), Shanghai, Shanghai Municipality, 200433, China
Sichuan
Sichuan Cancer hospital ( Site 2628), Chengdu, Sichuan, 610041, China
West China Hospital of Sichuan University ( Site 2610), Chengdu, Sichuan, 610041, China
The Second People's Hospital of Yibin ( Site 2629), Yibin, Sichuan, 644000, China
Tianjin Municipality
Tianjin Medical University Cancer Institute and Hospital-lung cancer ( Site 2606), Tianjin, Tianjin Municipality, 300060, China
Zhejiang
The First Affiliated Hospital, Zhejiang University-Respiratory Department ( Site 2613), Hangzhou, Zhejiang, 310003, China
Sir Run Run Shaw Hospital-Medical Oncology ( Site 2615), Hangzhou, Zhejiang, 310016, China
Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, 310022, China
The Second Affiliated hospital of Zhejiang University school of medicine-Respiratory Medicine ( Site, Hangzhou, Zhejiang, 310052, China
Antioquia
Fundación Colombiana de Cancerología Clínica Vida ( Site 0603), Medellín, Antioquia, 050030, Colombia
Bogota D.C.
Administradora Country S.A. - Clinica del Country ( Site 0601), Bogotá, Bogota D.C., 110221, Colombia
Cesar Department
Sociedad De Oncologia Y Hematologia Del Cesar ( Site 0606), Valledupar, Cesar Department, 200001, Colombia
Departamento de Córdoba
Oncomedica S.A.-Oncomedica S.A ( Site 0609), Montería, Departamento de Córdoba, 230001, Colombia
Risaralda Department
Oncologos del Occidente ( Site 0608), Pereira, Risaralda Department, 660001, Colombia
Centre-Val de Loire
CENTRE HOSPITALIER REGIONAL D'ORLEANS-Service de Pneumologie ( Site 0806), Orléans, Centre-Val de Loire, 45067, France
Haute-Savoie
Centre Hospitalier d'Annecy ( Site 0807), Epagny Metz-Tessy, Haute-Savoie, 74370, France
Hauts-de-France
Centre Hospitalier Regional Universitaire de Lille - Hôpital-Service de pneumologie et oncologie th, Lille, Hauts-de-France, 59037, France
Maine-et-Loire
Institut de Cancérologie de l'Ouest ( Site 0802), Angers, Maine-et-Loire, 49055, France
Rhone
CENTRE LEON BERARD ( Site 0803), Lyon, Rhone, 69373, France
Var
HIA Sainte Anne ( Site 0804), Toulon, Var, 83800 Cedex 9, France
Vaucluse
Centre Hospitalier d'Avignon ( Site 0810), Avignon, Vaucluse, 84000, France
Hesse
UKGM Gießen/Marburg-Medical Clinic V ( Site 0912), Giessen, Hesse, 35392, Germany
North Rhine-Westphalia
GEFOS Gesellschaft f. onkologische Studien ( Site 0909), Dortmund, North Rhine-Westphalia, 44263, Germany
Schleswig-Holstein
Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 0902), Lübeck, Schleswig-Holstein, 23538, Germany
Thuringia
SRH Wald-Klinikum Gera ( Site 0911), Gera, Thuringia, 07548, Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0913, Berlin, 13353, Germany
Rambam Health Care Campus-Oncology ( Site 1303), Haifa, 3109601, Israel
Shaare Zedek Medical Center-Oncology ( Site 1306), Jerusalem, 9013102, Israel
Meir Medical Center-oncology ( Site 1301), Kfar Saba, 4428164, Israel
Sheba Medical Center-ONCOLOGY ( Site 1302), Ramat Gan, 5265601, Israel
Sourasky Medical Center-Oncology ( Site 1305), Tel Aviv, 6423906, Israel
Ehime
National Hospital Organization Shikoku Cancer Center ( Site 2414), Matsuyama, Ehime, 791-0280, Japan
Ehime University Hospital ( Site 2411), Tōon, Ehime, 791-0295, Japan
Hyōgo
Hyogo Cancer Center-Thoracic Oncology ( Site 2409), Akashi, Hyōgo, 673-8558, Japan
Ishikawa-ken
Kanazawa University Hospital ( Site 2407), Kanazawa, Ishikawa-ken, 920-8641, Japan
Kanagawa
Kanagawa cancer center-Department of Thoracic Oncology ( Site 2405), Yokohama, Kanagawa, 241-8515, Japan
Miyagi
Miyagi Cancer Center ( Site 2401), Natori-shi, Miyagi, 981-1293, Japan
Osaka
Kansai Medical University Hospital ( Site 2415), Hirakata, Osaka, 573-1191, Japan
Saitama
Saitama Prefectural Cancer Center ( Site 2406), Ina-machi, Saitama, 362-0806, Japan
Shizuoka
Shizuoka Cancer Center ( Site 2408), Nakatogari, Shizuoka, 411-8777, Japan
Tokyo
Japanese Foundation for Cancer Research ( Site 2402), Koto, Tokyo, 135-8550, Japan
Showa University Hospital ( Site 2403), Shinagawa, Tokyo, 1428666, Japan
National Hospital Organization Kyushu Medical Center ( Site 2413), Fukuoka, 810-8563, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2412), Fukuoka, 811-1395, Japan
Okayama University Hospital ( Site 2410), Okayama, 700-8558, Japan
Nippon Medical School Hospital ( Site 2404), Tokyo, 113-8603, Japan
Coahuila
CENTRO DE INFUSION E INVESTIGACION ONCOLOGIA DE SALTILLO S.C. ( Site 0304), Saltillo, Coahuila, 25279, Mexico
Jalisco
Hospital Civil Fray Antonio Alcalde ( Site 0307), Guadalajara, Jalisco, 44280, Mexico
Mexico City
Arké SMO S.A. de C.V. ( Site 0301), Mexico City, Mexico City, 06700, Mexico
Alivia Clínica de Alta Especialidad ( Site 0310), Mexico City, Mexico City, 06760, Mexico
Greater Poland Voivodeship
Przychodnia Lekarska KOMED ( Site 1902), Konin, Greater Poland Voivodeship, 62-500, Poland
Med-Polonia Sp. z o. o. ( Site 1909), Poznan, Greater Poland Voivodeship, 60-693, Poland
Kuyavian-Pomeranian Voivodeship
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1903), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Masovian Voivodeship
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier, Warsaw, Masovian Voivodeship, 02-781, Poland
Centrum Medyczne Ostrobramska NZOZ Magodent ( Site 1908), Warsaw, Masovian Voivodeship, 04-125, Poland
Podkarpackie Voivodeship
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1904), Przemyśl, Podkarpackie Voivodeship, 37-700, Poland
Pomeranian Voivodeship
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 1906), Prabuty, Pomeranian Voivodeship, 82-550, Poland
Silesian Voivodeship
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1907), Bystra, Silesian Voivodeship, 43-360, Poland
Jeonranamdo
Chonnam National University Hwasun Hospital-Pulmonology ( Site 2201), Hwasun, Jeonranamdo, 58128, South Korea
Pusan-Kwangyokshi
Pusan National University Hospital ( Site 2205), Busan, Pusan-Kwangyokshi, 49241, South Korea
Seoul
Asan Medical Center ( Site 2206), Songpa-gu, Seoul, 05505, South Korea
Taegu-Kwangyokshi
Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2202), Deagu, Taegu-Kwangyokshi, 41404, South Korea
Taejon-Kwangyokshi
Chungnam national university hospital-Department of Internal Medicine ( Site 2203), Daejeon, Taejon-Kwangyokshi, 35015, South Korea
Korea University Guro Hospital-Internal Medicine ( Site 2204), Seoul, South Korea
La Coruna
CHUAC-Hospital Teresa Herrera-MEDICAL ONCOLOGY ( Site 1106), A Coruña, La Coruna, 15006, Spain
Las Palmas
Hospital Insular de Gran Canaria-Oncology ( Site 1102), Las Palmas de Gran Canaria, Las Palmas, 35001, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, 08035, Spain
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, 28040, Spain
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1103), Seville, 41009, Spain
Hospital Clínico Universitario Lozano Blesa-Oncology ( Site 1105), Zaragoza, 50009, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 2254), Kaohsiung City, 807, Taiwan
China Medical University Hospital ( Site 2253), Taichung, 40447, Taiwan
NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2252), Tainan, 704, Taiwan
National Taiwan University Hospital-Oncology ( Site 2255), Taipei, 100, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 2251), Taoyuan District, 333, Taiwan
Bangkok
Faculty of Medicine Siriraj Hospital ( Site 2304), Bangkok, Bangkok, 10700, Thailand
Chulabhorn Hospital ( Site 2305), Lak Si, Bangkok, 10210, Thailand
Changwat Khon Kaen
Faculty of Medicine - Khon Kaen University ( Site 2303), Muang, Changwat Khon Kaen, 40002, Thailand
Changwat Songkhla
Songklanagarind hospital ( Site 2302), Hat Yai, Changwat Songkhla, 90110, Thailand
Maharaj Nakorn Chiang Mai Hospital-Chiang Mai Clinical Trial Unit (CM-CTU) ( Site 2301), Chiang Mai, 50200, Thailand
Istanbul
Acibadem Altunizade Hospital-Oncology ( Site 1207), Üsküdar / Stanbul, Istanbul, 34662, Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1208), Adana, 01250, Turkey (Türkiye)
Hacettepe Universitesi-oncology hospital ( Site 1202), Ankara, 06230, Turkey (Türkiye)
Liv Hospital Ankara-Oncology ( Site 1205), Ankara, 06680, Turkey (Türkiye)
Ankara City Hospital ( Site 1204), Ankara, 06800, Turkey (Türkiye)
Trakya University-Medical Oncology ( Site 1203), Edirne, 22030, Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1209), Istanbul, 34722, Turkey (Türkiye)
Umraniye Training and Research Hospital-medical oncology ( Site 1206), Istanbul, 34766, Turkey (Türkiye)
England
Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 1502), Leicester, England, United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust-Research and Development ( Site 1501), London, England, SW10 9NH, United Kingdom
London, City of
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1506), London, London, City of, EC1A 7BE, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 1509), London-Camden, London, City of, NW1 2PG, United Kingdom